688046 GemPharmatech
- 10.88
- -0.37-3.29%
GemPharmatech News
An Intrinsic Calculation For GemPharmatech Co., Ltd. (SHSE:688046) Suggests It's 48% Undervalued
Pharmaron Biotech (688046.SH) will distribute cash dividends for the year 2023 on August 7, with a dividend of 0.16 yuan per share.
Pharmaron Biotech (688046.SH) announced that it will distribute its 2023 annual dividends on August 7, 2024.
Yao Kang Biological (688046.SH): Shareholder Qingdao National Medicine accumulatively reduced its shareholding by 1.0880%.
On July 31st, Gelunhui reported that PharmaKang Biological (688046.SH) received the Notification Letter of Shareholding Reduction from Qingdao National Pharmaceutical, a shareholder who owns more than 5% of the shares, on July 31st, 2024. Between October 31st, 2023 and July 31st, 2024, Qingdao National Pharmaceutical reduced its total shareholding in the company by 4.4608 million shares, or 1.0880% of the total share capital of the company, through block trading and centralized bidding.
Yaokang Biotechnology (688046.SH): Cumulative repurchase of 1.522 million shares of company's stock.
On July 31, Gelun Hui announced that Yakang Biotechnology (688046.SH) had repurchased a total of 1.522 million shares of the company through the Shanghai Stock Exchange trading system using the centralized competitive trading method, as of July 31, 2024, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price for repurchase transactions was 19.17 yuan/share, and the lowest price was 11.89 yuan/share. The total amount paid for this was RMB 23.8625 million yuan (excluding stamp duty, transaction commission and other transaction costs).
Yaokang Biotechnology (688046.SH): Spent a total of 23.86 million yuan to repurchase 0.3712% of shares.
On July 1st, Gelunhui announced that, by June 30th, 2024, the company had repurchased a total of 1,521,975 shares through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 0.3712% of the total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan/share and the lowest was 11.89 yuan/share, with a total payment of 23,862,462.57 yuan (excluding stamp duty, transaction commission and other transaction fees).
Is GemPharmatech (SHSE:688046) A Risky Investment?
Yaokang Biotechnology (688046.SH): Currently, the old production capacity is fully utilized, and new production capacity is gradually being added according to production plans.
PharmaKang Biological (688046.SH) stated on the investor interaction platform on June 18th that the company operates seven large-scale production facilities in Nanjing, Jiangsu, Changzhou, Jiangsu, Foshan, Guangdong, Chengdu, Sichuan, Daxing, Beijing, and Baoshan, Shanghai, with a total capacity of approximately 280,000 cages, of which 80,000 cages are newly added capacity in 2023. Currently, the old capacity is at full production, and the new capacity is climbing according to the production plan.
Yaokang Biotechnology (688046.SH): Qingdao National Medicine plans to reduce its shareholding by no more than 1.5%.
PharmaKang Biological (688046.SH) announced on June 7 that, due to its own funding needs, Qingdao Guoyao intends to reduce its shareholding in the company through block trading, with a total reduction of no more than 6,150,000 shares, or 1.50% of the total share capital of the company. The reduction will be carried out within three months after 15 trading days from the date of this announcement.
The major shareholder of Pharmaron Biological (688046.SH), Qingdao State Pharmaceutical Co., Ltd., plans to reduce its shareholding by no more than 1.5%.
Pharmaron Biotech (688046.SH) announced that Qingdao National Medicine Venture Capital Investment Partnership (...) holds more than 5% of the company's shares.
Yakkang Biotech (688046.SH): A total cost of 238.625 million yuan to buy back 0.3712% of shares
Gelonghui, May 31, 丨 Yakang Biotech (688046.SH) announced that as of May 31, 2024, the company had repurchased a total of 1,521,975 shares through the Shanghai Stock Exchange trading system, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 23,862,462.57 (excluding transaction fees such as stamp duty and transaction fees).
Should Weakness in GemPharmatech Co., Ltd.'s (SHSE:688046) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Yakkang Biotech (688046.SH): A total of 1,522,000 company shares were purchased at a cost of 238.625 million yuan
Gelonghui, April 30, 丨 Yakang Biotech (688046.SH) announced that as of April 30, 2024, the company had repurchased 1,522,000 shares of the company's shares through centralized bidding transactions, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 238.625 million (excluding transaction fees such as stamp duty and transaction fees).
Yakkang Biotech (688046.SH): Net profit of 294.79 million yuan in the first quarter decreased by 5.06% year-on-year
On April 26, Gelonghui (688046.SH) released its first quarter report. Operating revenue was 157 million yuan, up 11.96% year on year, net profit was 294.79 million yuan, down 5.06% year on year, after deducting non-net profit of 22.868 million yuan, up 2.74% year on year, with basic earnings of 0.07 yuan per share.
Zhitong A Share Sale Restriction and Release List | April 25
According to the Zhitong Finance App, the ban on restricted shares of 3 listed companies was lifted on April 25, with a total market value of about 647 million yuan. Today's specific sales restrictions and unbanned stocks are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Jiechang drives 60,3583 shares incentive sales restrictions and circulation 2375, Wan Rongqi Technology 301,360 shares are restricted in sale and circulation before issuance, 1,244,600, 10,000, Yakang Biotech 68,046 million
Yakkang Biotech (688046.SH): The ban on 2 million restricted shares was lifted on April 25
On April 16, Gelonghui (688046.SH) announced that the total number of shares in circulation in the company's current stock listing is 2 million shares. The stock listing and circulation date is April 25, 2024.
Yakkang Biology (688046.SH): No plans to directly enter the field of gene modification therapy
Gelonghui, April 8, 丨 Yakang Biology (688046.SH) said on the investor interactive platform that gene editing technology, as an underlying technology, can be applied in a wide range of fields. The company is closely monitoring technological progress and industry trends. The company is temporarily focusing on the field of model animals and has no plans to directly enter the field of gene modification treatment.
Yakkang Biotech (688046.SH): spent 238.625 million yuan to buy back a total of 1,522,000 shares
Gelonghui, April 2, 丨 Yakang Biotech (688046.SH) announced that as of March 31, 2024, the company had repurchased 1,522,000 shares of the company's shares through centralized bidding transactions, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 238.625 million (excluding transaction fees such as stamp duty and transaction fees).
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
Yakkang Biotech (688046.SH): A total cost of 238.267 million yuan to buy back 0.37% of the shares
Gelonghui, March 1, 丨 Yakang Biotech (688046.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,519,302 shares through the Shanghai Stock Exchange trading system, accounting for 0.3706% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 23,826,723.29.
Yakkang Biotech (688046.SH) performance report: 2023 net profit of 159 million yuan decreased by 3.46% year-on-year
On February 23, Ge Longhui (688046.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 622 million yuan, an increase of 20.45% over the same period of the previous year; realized net profit attributable to owners of the parent company of 159 million yuan, a decrease of 3.46% over the same period of the previous year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 107 million yuan, an increase of 5.09% over the same period last year.
Analysis
Price Target
No Data
